The Global Health Body Sounds Warning Over Critical Shortage of Weight-Loss Jabs
Less than 10% of individuals who could benefit from GLP-1 drugs such as Wegovy are able to get them, states the WHO as it issues its initial guidance on the therapies.
Given more than one billion individuals worldwide now obese, it is calling for more widespread and fairer access to this class of drugs.
According to projections, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.
"Our latest guidelines affirms that excess weight is a long-term condition that can be treated with holistic and continuous support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are key hurdles to universal availability to the jabs that can assist patients in reducing considerable body mass, explains the body.
Weight-Loss Drug Shortage
Despite the current best projected scenario, the manufacturing of such drugs would only suffice for around 100 million people – under 10% of those who need them, according to the WHO.
The guideline calls on governments and firms to expand access, through measures such as licensing agreements.
Exclusive production rights on semaglutide – the main component of a leading brand – is due to expire in several nations in 2026.
The Way Weight-Loss Jabs Function
The injections imitate a body's own hormone to slow digestion, reduce hunger and boost the sense of being full so users eat less.
Individuals commonly start to lose weight in the initial weeks of beginning the regular doses.
Research indicates patients may see weight return after a year of halting the medication, when their normal appetite return.
To be above a healthy weight raises your chance for experiencing diseases, including diabetes, heart disease, brain attack, and specific malignancies.
Obesity affects individuals in all nations and was associated with millions of deaths worldwide in 2024, as per the health agency.
